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Abstract
The main challenge for gaining biological insights from genetic associations is identifying which 
genes and pathways explain the associations. Here we present DEPICT, an integrative tool that 
employs predicted gene functions to systematically prioritize the most likely causal genes at 
associated loci, highlight enriched pathways and identify tissues/cell types where genes from 
associated loci are highly expressed. DEPICT is not limited to genes with established functions 
and prioritizes relevant gene sets for many phenotypes.
The causal variants, genes and pathways in many genomewide association studies (GWAS) 
loci often remain elusive, due to linkage disequilibrium (LD) between associated variants, 
long-range regulation and incomplete biological knowledge of gene function. To translate 
genetic associations into biological insight, we need at a minimum to identify the genes that 
account for associations as well as the pathways and tissue/cell type context(s) in which the 
genes’ actions affect phenotypes. Although cell-type-specific expression quantitative trait 
loci (eQTLs) or coding (non-synonymous) variants in strong LD with associated variants 
can potentially link these variants to genes, overlap with eQTLs or coding variants may be 
coincidental. In addition, coding variants in high LD with associated variants are rarely 
observed, and eQTL data from non-haematological cell types are rare. Direct functional 
follow-up of the many potentially causal variants and genes is typically difficult and 
expensive, so an attractive first step is to use computational approaches to prioritize genes in 
associated loci with respect to their likely biological relevance, and to identify pathways and 
tissues to define their likely biological context. The current paradigm for gene prioritization 
methods is to systematically search for commonalities in functional annotations between 
genes from different associated loci, such as shared features derived from text mining1 
(which is limited by the literature’s highly incomplete characterization of gene function) or 
propensity to interact at the protein level2 (which is unlikely to capture the full functional 
spectrum of a given gene or phenotype3). The paradigm for gene set analysis is to search for 
enrichment of the genes near associated variants in manually curated gene sets or in gene 
sets derived from molecular evidence4. Although certain pathways have been carefully 
characterized, and manually curated gene sets and protein–protein interaction maps can be 
of great value, pathway annotation of genes remains sparse and skewed towards well-studied 
genes5. At the same time, the availability of large, diverse, genome-wide data sets, such as 
gene expression data, can elucidate and annotate potential functional connections between 
genes6. Given these limitations and opportunities, and the wide spectrum of traits and 
diseases analysed in association studies, there is a need for a general computational 
approach that integrates diverse, non-hypothesis-driven data sets to prioritize genes and 
pathways7,8.
With the goal of meeting this need, we develop and hereby present a framework called Data-
driven Expression Prioritized Integration for Complex Traits (DEPICT, 
www.broadinstitute.org/depict), which is not driven by phenotype-specific hypotheses and 
considers multiple lines of complementary evidence to accomplish gene prioritization, 
pathway analysis and tissue/cell type enrichment analysis. This framework can prioritize 
genes, pathways and tissue/cell types across many different phenotypes9–13.
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Results
Overview of the DEPICT methodology
DEPICT builds on our recent work that used co-regulation of gene expression (derived from 
expression data of 77,840 samples), in conjunction with previously annotated gene sets, to 
accurately predict gene function based on a ‘guilt-by-association’ procedure6. We first 
expanded this approach to include 14,461 existing gene sets, representing a wide spectrum 
of biological annotations (including manually curated pathways14–16, molecular pathways 
from protein–protein interaction screens17 and phenotypic gene sets from mouse gene 
knock-out studies18). By calculating, for each gene, the likelihood of membership in each 
gene set (based on similarities across the expression data; see Methods), we generated 
14,461 ‘reconstituted’ gene sets (see Fig. 1; Supplementary Data 1). Rather than traditional 
binary gene sets (genes are included or not included), these reconstituted gene sets contain a 
membership probability for each gene in the genome; conversely, a gene is functionally 
characterized by its membership probabilities across the 14,461 reconstituted gene sets. 
Using these precomputed gene functions and a set of trait-associated loci, DEPICT assesses 
whether any of the 14,461 reconstituted gene sets are significantly enriched for genes in the 
associated loci, and prioritizes genes that share predicted functions with genes from the 
other associated loci more often than expected by chance. In addition, DEPICT utilizes a set 
of 37,427 human microarrays to identify tissue/cell types in which genes from associated 
loci are highly expressed. DEPICT uses precomputed GWAS based on randomly distributed 
phenotypes to take sources of confounding into account: it extracts gene-density-matched 
input loci from these ‘null GWAS’, recomputes results and adjusts the P values from the 
above three analyses for null expectation. It also uses the null GWAS to adjust for multiple 
testing by computing false discovery rates (FDRs, see Methods).
Calibration of locus definitions
Having developed this framework, we first considered a key feature, the definition of an 
associated locus—that is, given an associated variant, how many of the nearby genes should 
be taken into consideration as potentially causal? Using as a positive control Mendelian 
disease genes that affect skeletal growth and are over-represented in height-associated 
GWAS loci10,19, we evaluated DEPICT’s performance using loci defined by different 
combinations of genetic and physical distance from the lead associated variant 
(Supplementary Data 2). We found that a locus definition of r2>0.5 from the lead variant 
was optimal (Supplementary Note 1). We repeated the analysis using genome-wide-
significant associations for low-density lipoprotein (LDL) cholesterol20 and 14 Mendelian 
lipid genes20 as positive controls and observed similar results (r2>0.4), indicating that the 
calibration does not change drastically for other traits (Supplementary Data 3).
Type-1 error rate analysis
We next tested whether DEPICT properly controls the type-1 error rate. Running DEPICT 
with random input loci based on either real genotype or simulated genotype data, we 
observed nearly uniform distributions for gene set enrichment, gene prioritization and tissue/
cell type enrichment P values (see Supplementary Fig. 1 and Methods). Importantly, we did 
not observe any correlation between gene length and gene prioritization P values (Spearman 
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r2 = 7.70 × 10−5), nor correlation with locus gene density (Spearman r2 = 7.53 × 10−8), two 
factors that have often confounded pathway analyses21. We also did not observe any 
correlation between tissue/cell type enrichment P values and the number of samples 
available in the expression data sets for each annotation (Spearman r2 = 6.9 × 10−4), nor 
were results dependent on the particular set of genotype data used to construct the null 
GWAS (Supplementary Note 2). Together, these results indicated that DEPICT results are 
not driven by bias in its data sources.
Benchmarking the gene set enrichment framework
We next compared DEPICT with two GWAS pathway methods, MAGENTA22 and 
GRAIL1 using GWAS results for three phenotypes, each with >50 independent genome-
wide significant single-nucleotide polymorphisms (SNPs): Crohn’s disease23, human 
height10 and LDL20. DEPICT’s gene set enrichment functionality outperformed 
MAGENTA (a widely used GWAS gene set enrichment tool) by identifying more relevant 
gene sets (both methods exhibited comparable type-1 error rates; Supplementary Figs 1 and 
2) for all three phenotypes: DEPICT identified 2.5 times as many significant gene sets 
(FDR<0.05) for Crohn’s disease, 2.8 times as many significant gene sets for height and 1.1 
times as many significant gene sets for LDL (Fig. 2; Supplementary Figs 3–5; 
Supplementary Data 4–6). Many gene sets prioritized by DEPICT, but not MAGENTA, 
appear biologically relevant (for example, regulation of immune response, response to 
cytokine stimulus and toll-like receptor signalling pathway for Crohn’s disease; Fig. 2). To 
test whether our gene set reconstitution strategy was driving the performance differences 
between MAGENTA and DEPICT, we ran MAGENTA with non-probabilistic, binary 
(yes/no) versions of the reconstituted gene sets (see Methods). We found a consistent 
increase in the number of nominally significant gene sets when MAGENTA was run with 
reconstituted gene sets for Crohn’s disease, height and LDL (1.4, 1.6 and 1.7-fold increases, 
respectively, in number of nominally significant gene sets using the 95 percentile model; 
Supplementary Data 4–6; Supplementary Figs 6–8). To assess whether the reconstituted 
gene sets enhance the performance of DEPICT, we ran DEPICT using the original, 
predefined gene sets. As expected, the number of prioritized gene sets (FDR<0.05) dropped 
to 97.7, 92.9 and 20% for the Crohn’s disease, height and LDL analyses, respectively 
(Supplementary Data 4–6). Together, these analysis indicate that the gene set reconstitution, 
combined with DEPICT’s ability to use probabilistic gene sets, is responsible for the 
increased performance of DEPICT compared with MAGENTA in gene set enrichment 
analysis.
Benchmarking the gene prioritization framework
Using gene lists from whole-blood expression quantitative locus data24, rodent growth plate 
differential expression data25 and Mendelian human lipid genes reported in literature20 (see 
Methods), we constructed positive sets of genes to compare DEPICT’s gene prioritization 
performance with GRAIL (a widely used GWAS gene prioritization tool). DEPICT and 
GRAIL performed similarly in analyses based on all genome-wide significant loci with at 
least one positive gene, based on area under a receiver-operating characteristic (ROC) curve 
(AUC, Table 1; Supplementary Datas 7–9; Supplementary Fig. 9). However, when 
restricting the height comparison with loci with no well-known Mendelian human skeletal 
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growth gene, DEPICT markedly outperformed GRAIL, prioritizing genes at many more loci 
(DEPICT: 1.1 genes per locus, GRAIL: 0.4 genes per locus), suggesting that DEPICT 
performs better at loci harbouring genes with less well-established roles in literature 
(Supplementary Data 10). We validated this observation using genes nearest to height-
associated SNPs as positive genes at these loci. The nearest gene is an unbiased, but highly 
imperfect benchmark (for example, only 13/21 Mendelian skeletal growth genes in a large 
height GWAS19 were the nearest genes to a height-associated SNP), so AUC is expected to 
be low using this benchmark. Nonetheless, DEPICT not only prioritized more genes than 
GRAIL, but also had a higher AUC (Supplementary Data 11). Finally, DEPICT performed 
consistently better than a gene expression-based version of GRAIL (Supplementary Data 7–
9), indicating that use of gene expression data in the prediction is not driving DEPICT’s 
superior performance across several of the comparisons. Together, these analyses indicate 
that DEPICT performs particularly well for gene prioritization at what are arguably the most 
important loci for new discovery: those with biology that is less well captured in already 
published literature.
Prioritization of genes outside genome-wide significant loci
We hypothesized that DEPICT could also be used to prioritize genes outside genome-wide 
significant loci, based on predicted functional relatedness to genes within genome-wide 
significant loci. Similar to the gene prioritization implemented in DEPICT, we prioritized 
genes with higher than expected pairwise similarities to genes from trait-associated loci 
(across the 14,461 functional predictions; see Methods). SNPs within or near (± 50 kb) the 
3,022 genes that were functionally related to Crohn’s disease loci genes (at FDR < 0.05) had 
lower association P values than SNPs in the same number of unrelated genes (genes with 
FDR>0.99; genomic inflation factor λ=1.49 versus λ= 1.31), indicating that DEPICT 
enriches for as-yet-unidentified genes associated with Crohn’s disease. The enrichment was 
further increased when considering only SNPs that overlap with eQTLs in whole blood24 (λ 
= 1.69 versus λ = 1.25). A similar enrichment of associations was seen for height (λ = 1.92 
versus λ = 1.62) and LDL (λ = 1.06 versus λ = 0.97).
To begin to assess the performance and specificity of DEPICT across a wider range of 
phenotypes, we applied DEPICT to 61 phenotypes in the NHGRI GWAS Catalog26 that had 
at least 10 genome-wide-significant (unadjusted association P value < 5 × 10−8) 
associations. DEPICT identified at least one significantly enriched (P value <10−6, the 
Bonferroni-corrected significance threshold) reconstituted gene set for 39 of the 61 
phenotypes (Fig. 3; Supplementary Data 12). To test whether DEPICT identified similar 
gene sets for related phenotypes, we clustered the 39 traits based on their gene set 
enrichment scores across the 14,461 reconstituted gene sets (Fig. 3). Related traits clustered 
with each other, but different phenotypes yielded quite different gene sets. Furthermore, 
many of the top gene sets were of clear relevance to the phenotype (Supplementary Data 
12). Thus, DEPICT is able to identify, with specificity, biologically relevant gene sets for a 
wide range of human traits and diseases. Consistent with these results, we recently used 
DEPICT to analyse GWAS data for height, body mass index and waist-hip ratio adjusted for 
body mass index (from the GIANT Consortium)10,12,13 and for hypospadias9. For each 
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phenotype, DEPICT highlighted a distinct and biologically meaningful group of known and 
novel genes, gene sets and tissue/cell types.
Discussion
We present a computational framework called DEPICT, which enables gene prioritization, 
gene set enrichment analysis and tissue/cell type enrichment analysis to generate specific 
testable hypotheses that are critical to inform experimental follow-up of GWAS. DEPICT 
implements these three distinct functionalities into a single, publicly available tool. Apart 
from providing useful insights into pathways and biological annotations of relevance to a 
phenotype, a key application of the gene set enrichment functionality is to use it for 
selecting in vitro phenotypes that may serve as readouts in cellular assays used to validate 
prioritized genes for a complex trait. A key advantage of DEPICT over existing tools is the 
gene set reconstitution, which enables prioritization of previously poorly annotated genes, as 
well as more specific and powerful gene set enrichment analysis. By using data sets and 
methods that are not specific to any particular disease or trait, DEPICT does not depend on 
phenotype-specific hypotheses (for example, particular neuronal gene sets being important 
for schizophrenia).
On the basis of our current experience, we recommend employing DEPICT on genome-wide 
significant loci as well as all loci with association P values < 10−5 (see Supplementary Fig. 
10 for results based on LDL loci using the relaxed threshold and for an example on 
visualizing DEPICT results). We also recommend a locus definition of r2 > 0.5 from lead 
SNPs. It is important to note that reconstituted gene sets should be interpreted in light of the 
genes that are mapped to them, rather than strictly by their identifiers (which are carried 
over from the predefined gene sets).
Despite DEPICT’s ability to identify relevant gene sets for a large number of traits and 
diseases, the method may be less sensitive to phenotypes caused by genes that have 
specialized functions that cannot be well predicted based on integrating gene expression data 
with the currently existing predefined gene sets. Indeed, there are multiple ways in which 
the DEPICT framework could be improved further. Additional future work includes 
iteratively conditioning on significant genes, gene sets and tissue/cell types to enhance 
prioritization of genes with weaker, yet significant, relationships, and quantification of the 
relative importance of significant predictions. Additional expression data would enhance the 
data sources available for DEPICT, especially for prioritization of tissues/cell types. Other 
data types, such as epigenetic data, have yet to be integrated into the DEPICT framework, 
and DEPICT does not yet use information that could further prioritize genes within loci, 
such as LD with eQTLs or missense variation, or being the nearest gene to the lead SNP. 
Finally, DEPICT is currently optimized for GWAS results, but could be adapted to other 
types of data sets (custom arrays, exome chip or sequencing).
In conclusion, there is a need for approaches that are not driven by phenotype-specific 
hypotheses and that consider multiple lines of complementary evidence to accomplish gene 
prioritization, pathway analysis and tissue/cell type enrichment analysis. We have developed 
a computational and publicly available tool—DEPICT—that can address this need by 
Pers et al. Page 6
Nat Commun. Author manuscript; available in PMC 2015 May 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
performing integrative analysis, thereby generating novel, testable hypotheses from genetic 
association studies across a wide spectrum of traits and diseases.
Methods
Data and software availability
The following sections describe the DEPICT methodology in detail. DEPICT source code 
and example data are available at https://github.com/DEPICTdevelopers. Ready-to-use 
software is available at www.broadinstitute.org/depict.
Definition of associated loci
From the set of associated SNPs at a particular threshold (such as genome-wide significance, 
P<5 × 10−8), we generated independent ‘lead SNPs’ by retaining the most significant SNP 
from each set of SNPs that are in LD (pairwise r2>0.1) and/or in proximity (physical 
distance of < 1 Mb). We computed pairwise LD coefficients based on the imputation panel 
used in the GWAS, either HapMap Project release 2 and 3 CEU genotype data27 or 1000 
Genomes Project Phase 1 CEU, GBR and TSI genotype data28. We defined positions in the 
human genome according to genome build GRCh37. Next, we created lists of genes at 
associated loci by mapping genes to loci if they resided within, or were overlapping with, 
boundaries defined by the most distal SNPs in either direction with LD r2>0.5 to the given 
lead SNP (see Supplementary Note 1 for justification of this locus definition). If no genes 
were within the locus defined by r2 > 0.5, the gene nearest to the given lead SNP was 
included. Loci with overlapping genes were then merged. Due to the extended LD in the 
major histocompatibility complex region and the resulting challenges in delineating 
associated loci, genes within base pairs 25,000,000–35,000,000 on chromosome 6 were 
excluded. DEPICT takes as input a set of independent, associated SNPs and automates all 
other steps outlined here.
Gene sets used in DEPICT
DEPICT is based on a large number of predefined gene sets from diverse databases and data 
types (Supplementary Data 1). Gene ontology15, Kyoto encyclopedia of genes and 
genomes14 and REACTOME16 gene sets were mapped to Ensembl database identifiers. 
Molecular pathways were constructed based on experimentally derived high-confidence 
protein–protein interactions from the InWeb database17 by considering each of the 12,793 
genes in the database and annotating direct, high-confidence interaction partners of a given 
gene as a molecular pathway (including the given gene itself). We defined high-confidence 
interactions as pairs of gene products with InWeb-specific protein–protein interaction 
confidence scores above 0.154, a cutoff previously justified17. In addition, we constructed 
2,473 phenotypic gene sets based on 211,882 phenotype–gene relationships from the Mouse 
Genetics Initiative18. These gene sets were constructed by adding genes to the same gene set 
if they were related to the same Mouse Genetics Initiative phenotype. From all repositories, 
we only included gene sets with at least 10 genes and at most 500 genes.
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Gene function prediction for gene set reconstitution
DEPICT performs gene prioritization and gene set enrichment based on predicted gene 
function and reconstituted gene sets (note that the reconstituted gene sets are a consequence 
of the gene function prediction). Please refer to Fehrmann et al.6 (and www.genenetwork.nl) 
for a detailed description of the gene function prediction method. The main hypothesis 
behind the gene function prediction follows a guilt-by-association logic: a gene that is co-
regulated with say 20 other genes, which perform a specific function, is likely to exhibit the 
same function. In Fehrmann et al.6, we developed an approach that quantifies co-regulation 
between pairs of genes based on gene expression data, even in instances where 
transcriptomic co-regulation is subtle. In Fehrmann et al.6, we conducted the following steps 
to predict functions of genes and construct reconstituted gene sets:
1. We first renormalized 77,840 microarrays from two human, one rat and one mouse 
Affymetrix gene expression platform downloaded from the Gene Expression 
Omnibus (GeO) database29 (Supplementary Data 13).
2. We constructed a probe–probe correlation matrix (using Pearson correlation to 
compute all pairwise probesets correlations) for each of the four platforms.
3. We performed principal component analysis on each of the four correlation 
matrices, and used Cronbach’s Alpha and Split-half reliability statistics to retain 
777 and 377 eigenvectors (hereafter ‘transcriptional components’ or ‘TCs’; 
Fehrmann et al.6) from the two human platforms, 677 TCs from the mouse 
platform and 375 TCs from the rat platform.
4. We mapped all human genes to Ensembl identifiers30; mouse and rat genes were 
mapped to their human homologues (Ensembl database orthology mapping). The 
loadings of each gene on each TC are the elements of a gene-TC matrix with 
19,997 gene rows (the number of genes covered by the Affymetrix platforms) and 
2,206 TC columns.
We then used the gene-TC matrix to predict 19,997 genes’ function across the 14,461 
functional annotations represented by the predefined gene sets, by doing the following steps:
1. For each gene set, we computed the enrichment on each TC (using z-scores derived 
from Welch’s t-test to assess whether the TC loadings from genes from the given 
set significantly deviated from all other genes’ loadings). This resulted in a TC 
profile for each gene set (a gene set-TC matrix of z-scores with 14,461 gene set 
rows and 2,206 TC columns).
2. To obtain gene function predictions and reconstituted gene sets, we quantified each 
gene’s likelihood of being part of a given predefined gene set by correlating the 
gene’s 2,206 TC loadings (from the gene-TC matrix) with the z-score TC profile of 
each gene set (from the gene set-TC matrix). To avoid circularity in cases where a 
particular gene was part of a predefined gene set, we left out that gene from the 
gene set, recomputed the gene set z-score profiles along all TCs and then computed 
the correlation of the gene with the gene set.
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3. We converted the correlation P values to z-scores to obtain a gene-gene set matrix 
of z-scores comprising 19,997 gene rows and 14,461 gene sets columns. This 
matrix is used by DEPICT to perform gene prioritization and gene set enrichment 
analysis.
Null GWAS construction
To take sources of confounding into account, DEPICT makes use of precomputed GWAS 
based on randomly distributed phenotypes to (‘null GWAS’). We computed 200 GWAS 
based on genome-wide CEU genotype data from the Diabetes Genetics Initiative31 (DGI) 
and simulated Gaussian phenotypes (random draws from N(0,1) distribution) with no 
genetic basis.
DEPICT gene prioritization
For gene prioritization, DEPICT employs a phenotype- and mechanism-agnostic algorithm, 
which is predicated on a previously formulated assumption that truly associated genes share 
functional annotations1,17,32. In other words, genes within associated loci that are 
functionally similar to genes from other associated loci are the most likely causal candidates. 
DEPICT prioritizes genes based on three major steps: a scoring step, a bias adjustment step 
and a FDR estimation step. In the scoring step, the method quantifies the similarity of a 
given gene to genes from other associated loci by correlating their reconstituted gene set 
memberships (across all 14,461 gene sets). The bias adjustment step is designed to control 
inflation in gene scores caused by, for example, gene length (longer genes are more likely to 
be part of associated GWAS loci) or structure in the underlying expression data. In this step, 
the method normalizes the given gene’s similarity score based on the distribution of the 
given gene’s similarity to genes from 1,000 sets of gene-density-matched loci, derived from 
the 200 pre-permuted null GWAS. In the last step, experiment-wide FDRs are estimated by 
repeating the scoring and bias adjustment steps 20 times based on top SNPs from 
precomputed null GWAS. For a given gene (gene x) that has a prioritization P value y in the 
actual data, a FDR is calculated by first counting the number of genes having a P value 
smaller or equal to y across all 20 null runs and dividing this count by the rank of gene x in 
the actual data. We note that in the version of DEPICT implemented in the studies of 
anthropometric traits10,12,13, we included a correction for the number of genes at a given 
locus. Because this correction does not change gene prioritization results markedly (gene set 
enrichment results and tissue/cell type enrichment results are unchanged), we recommend 
not using this correction because it imposes an overly conservative correction on genes in 
relatively gene-poor loci. This correction was not implemented in the version described 
here.
DEPICT reconstituted gene set enrichment
The gene set enrichment analysis algorithm comprises the same three steps as employed in 
gene prioritization: a gene set scoring step, a bias correction step and a FDR estimation step. 
For a given reconstituted gene set, DEPICT quantifies enrichment by (1) summing the given 
gene set membership z-scores (entries in the gene-gene set matrix) of all genes within each 
associated locus and then computing the sum of sums across all loci; (2) repeating step 1 a 
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thousand times based on random loci that are matched by gene density, and using the 
thousand null z-scores to adjust the real z-score by subtracting their mean, dividing by their 
s.d. and converting the adjusted z-score to a P value; and (3) repeating steps 1 and 2 twenty 
times to estimate experiment-wide FDRs similar to the method described above.
DEPICT tissue/cell type enrichment analysis
DEPICT utilizes 37,427 human Affymetrix HGU133a2.0 platform microarrays 
(approximately half of the microarrays used to reconstituted gene sets) to assess whether 
genes in associated loci are highly expressed in any of the 209 Medical Subject Heading 
(MeSH) tissue and cell type annotations. The tissue/cell type expression matrix was 
constructed by averaging gene expression levels of microarray samples with the same MeSH 
annotation6. This process included N(0,1) normalizing across all tissue/cell type annotations 
to remove effects of ubiquitously expressed genes, N(0,1) normalizing the columns of the 
tissue/cell type expression matrix (to allow enrichment analysis identical to the gene set 
enrichment analysis framework) and retaining only tissue/cell type annotations covered by at 
least 10 microarrays. Conceptually, the resulting gene-tissue/cell type expression matrix 
resembles the gene-gene set matrix, the only difference being that columns represent the 
relative expression of genes in a given tissue compared with the other tissues, as opposed to 
the likelihood of membership of a gene in a gene set. Consequently, the tissue/cell type 
enrichment analysis algorithm is conceptually identical to the gene set enrichment analysis 
algorithm.
Adjusting for confounding sources
For a given set of associated loci from the ‘real GWAS’ (the study of interest), DEPICT 
extracts the same number of independent loci from the 200 precomputed null GWAS. For a 
given null GWAS, this is accomplished by varying the SNP association P value cutoff until 
the number of independent top loci is the same as the number of independent loci in the real 
GWAS. The independent top loci from each null GWAS are then collected into a single pool 
of loci. During the DEPICT gene prioritization, gene set enrichment and tissue/cell type 
enrichment analyses, this pool of loci is used to sample 1,000 collections of gene density-
matched ‘null loci’ (in each collection there are as many null loci as the number of loci 
observed in the real GWAS). Null loci within a given collection are not allowed to overlap 
(in terms of genes). During the DEPICT background correction step, if a locus from the real 
GWAS is represented by < 10 gene-density-matched null loci, DEPICT iteratively includes 
larger and smaller null loci (to avoid oversampling the same null loci during the 1,000 
background runs). We employed different numbers of null GWAS contributing to the pool 
of null loci, and observed no major differences between using 200, 500 or 900 null GWAS 
(Supplementary Note 3).
Type-1 error rate analyses
To compute type-1 error rates for the gene prioritization, gene set enrichment and tissue/cell 
type enrichment analyses, we first computed 100 DGI null GWAS the same way as describe 
in the above section. Spearman correlation coefficients were computed based on log10 
transformed P values. We used an alternate approach to estimate type-1 error by replacing 
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the null GWAS with simulated GWAS that have positive signals but no underlying 
biological basis. We simulated 50,000 individuals using HAPGEN33 using parameters from 
the HapMap Project release 3 CEU population. From this, we obtained 1,175,577 genotypes 
for all autosomes (chromosomes 1–22) and calculated the allele frequency for each SNP 
using the 50,000 individuals. We then randomly selected 1,000 SNPs to have an effect on 
the phenotype and assigned effect sizes such that all SNPs jointly explain 45% of the total 
variance. The effect size for each SNP was calculated as follows,
(1)
where β is the effect size in s.d. units, σ2 is the variance explained for each SNP,p is the 
SNP’s minor allele frequency and σ denotes a random variable with equal probability of 
being + 1 or − 1. Once each SNP’s effect size was determined, we calculated the weighted 
allele score for each individual by summing up the SNP minor allele dosages weighted by 
their effect size. The weighted allele score was calculated as follows,
(2)
where N is the number of SNPs (N = 1,000), βi is the effect size of the ith SNP as calculated 
earlier, SNPi is the dosage of the minor allele for the ith SNP (0,1 or 2) and pi is the minor 
allele frequency of the ith SNP. The subtraction of 2βipi served to adjust the weighted allele 
score such that its mean was 0. We obtained the final phenotypic z-score by adding a 
remaining noise term such that the total variance was 1. The z-score was calculated as 
follows,
(3)
where N(0, variance_remaining) is a randomly generated number sampled from a Normal 
(N) distribution with mean 0 and variance 0.55. This process was repeated 100 times to 
obtain 100 sets of phenotypic z-scores for each of the 50,000 individuals. We used PLINK34 
to perform GWAS on each set of phenotypes using the 50,000 simulated genotype samples, 
and then, for each null GWAS, identified the association P-value threshold that resulted in 
100 fully independent loci (DEPICT locus definition). Finally, we ran DEPICT with default 
settings on each of the n = 100 sets of input SNPs.
Crohn’s disease DEPICT analysis
Summary statistics from GWAS-based meta analysis of Crohn’s disease23 (downloaded 
from www.ibdgenetics.org) were used to identify genome-wide significant loci (using 
PLINK and parameters ‘–clump-kb 1000 –clump-r2 0.01’). As input to DEPICT we used the 
resulting 63 genome-wide significant (χ2-test P value < 5 × 10−8), which were located in 54 
fully independent loci based on DEPICT definitions of independence.
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Human height DEPICT analysis
As input we used 697 genome-wide significant human height associations identified in 
GWAS-based meta analysis10 (accessible through http://www.broadinstitute.org/
collaboration/giant), which were located in 566 fully independent loci based on DEPICT 
definitions of independence.
Low-density lipoprotein cholesterol DEPICT analysis
Summary statistics from GWAS-based meta analysis of LDL20 (downloaded from 
www.sph.umich.edu/csg/abecasis/public/lipids2010) were used to identify genome-wide 
significant loci (using PLINK with parameters ‘–clump-kb 1000 –clump-r2 0.01’). As input 
to DEPICT we used the resulting 67 independent loci, which resulted in 40 fully 
independent loci used DEPICT definitions of independence.
Gene set enrichment benchmark
Due to the lack of an unbiased set of gold standard pathways for any complex trait, we 
compared DEPICT and MAGENTA22 by counting the number of statistically significant 
gene sets predicted based on Crohn’s disease, height and LDL loci. Prior to the benchmark, 
we estimated the type-1 error rate of both methods by running them with summary statistics 
from 100 null GWAS constructed based on simulated Gaussian phenotypes with no genetic 
basis, and HapMap Project release 2 imputed DGI Consortium genotype data 
(Supplementary Figs 1 and 3). For the null analyses, the top 200 independent loci from each 
null GWAS were used as input, whereas genome-wide significant loci were used as input in 
the Crohn’s disease, height and LDL analyses. All MAGENTA runs were based on the 
complete set of summary statistics. We restricted the comparison to a list of 1,280 gene sets 
(gene ontology terms, Kyoto encyclopedia of genes and genomes and REACTOME 
pathways) with overlapping identifiers between both methods. DEPICT was run on 
reconstituted gene sets. MAGENTA was run with default settings and both methods 
excluded the major histocompatibility complex region. The non-probabilistic, binary 
(yes/no) version of the reconstituted gene sets used in one of the MAGENTA comparisons 
were constructed by applying a threshold on the gene scores for a given reconstituted gene 
set (all genes above a permutation-based cutoff were considered part of the given 
reconstituted gene sets, as reported in ref 6). Entries with ‘NA in columns ‘DEPICT with 
predefined gene sets P’ and ‘DEPICT with predefined gene sets FDR’ in Supplementary 
Data 4–6 marked predefined gene sets for which enrichment could not be computed in the 
DEPICT analysis based on predefined gene sets.
Gene prioritization benchmark
We ran each method (DEPICT and GRAIL1) using their default settings on all genome-wide 
significant Crohn’s disease23, height10 and LDL20 associations. To evaluate the methods’ 
performance on the same set of positive genes (genes that are highly likely to be causal to 
the phenotype) and negative genes (genes that are unlikely to be causal), we limited the 
comparison to loci at which there was at least one positive gene present across both 
methods, and discarded any genes at these benchmark loci that were not considered by each 
method. For the Crohn’s disease comparison, we used as positives 31 genes that were 
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transcriptionally regulated in whole blood24 by a genome-wide significant Crohn’s disease 
association or a SNP in high LD (r2 > 0.7) with a genome-wide significant SNP. For the 
height comparison, we used as positives a set of 44 genes that were within genome-wide 
significant height-associated loci and differentially expressed in rodent growth plate 
expression studies; we have previously shown that the rodent gene expression data are 
enriched for genes in height-associated loci25 (Supplementary Table 2 in Lango Allen et 
al.19). For the LDL comparison, we used as positives a set of seven genes with reported 
Mendelian mutations proposed to cause lipid-related traits20. For all three benchmarks, we 
removed negative genes that had a missense variant in strong LD (r2 > 0.7) with an 
associated SNP; for the height and LDL benchmarks, we removed negative genes that were 
transcriptionally regulated24 by a SNP in strong LD (r2 > 0.7) with an associated SNP; in the 
height benchmark, we removed negative genes that were differentially expressed in rodent 
growth plates versus other tissues, spatially regulated across different growth plate zones 
(hypertrophic versus proliferating, and proliferative versus resting) or temporally regulated 
in growth plates between week 12 and week 3 at nominal significance in reference25, and 
genes that were reported in the high-confidence list in ref. 19. After these steps, we were 
able to use 42 negative genes across 18 loci as Crohn’s disease benchmarks and 37 negative 
genes across 43 loci as height benchmarks. There were no negative genes among the seven 
LDL benchmark loci. Positive and negatives genes, are listed in Supplementary Data 7–9. 
Precision (the fraction of positive genes among all prioritized genes at a given P-value 
threshold) and recall (the fraction of correctly classified positive genes at a given P-value 
threshold also referred to as sensitivity) estimates were used to measures accuracy and 
summarized using the F-measure, which incorporates the ability to recall positive genes with 
a high precision into a single measure. (Maximum precision implies no false positives, 
whereas maximum recall implies no false negatives.) To measure the ability to discriminate 
positive and negative genes at a relative scale, we also computed ROC AUC estimates. To 
avoid circularity, the growth plate data25 and the eQTL data24 were not part of the data used 
by any of the three methods tested. The R software35 and the ROCR R library36 were used 
to construct the precision recall and ROC curves and the AUC estimates.
Prioritizing genes outside genome-wide significant loci
To enable prioritization of genes below the genome-wide significance threshold, we scored 
each gene outside the genome-wide significant loci with respect to its similarity to genes 
within associated loci. For a given gene outside genome-wide significant loci, we (1) 
correlated (Pearson) its predicted functions across all 14,461 gene sets to every gene in each 
of the trait-associated loci, (2) kept the lowest correlation P value from each genome-wide 
significant locus, (3) converted the P values to z-scores and (4) summed the z-scores and 
converted the sum back to a P value (alternative hypothesis: gene functionally related to 
genes in trait-associated loci). We computed FDRs, by redoing steps 1–4 based loci from 
null GWAS. Using FDR < 0.05 as the threshold, we identified 3,022, 5,916 and 1,901 
related genes for Crohn’s disease, height and LDL. For each of the three traits, we then 
calculated genomic inflation factors for SNP P values in the functionally related genes and 
for SNP P values in the same number of genes exhibiting the highest (non-significant) 
FDRs. We added 50 kb flanking loci to gene boundaries (defined by the boundaries of the 
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most extreme transcripts) and required genes to be at least 1 Mb away from the nearest 
genome-wide significant locus.
GWAS catalog analysis
The GWAS Catalog26 was downloaded from www.genome.gov/gwastudies/ (download 
date: 02 January 2014) and 61 phenotypes with at least 10 fully independent regions 
(DEPICT definitions) based on genome-wide associations were retained. Hierarchical 
clustering implemented in the R software method ‘hclust’ was run with default settings 
(method = ‘complete-linkage’, dist = ‘euclidean’). The DEPICT locus definitions for all 
GWAS catalog traits can be downloaded from www.broadinstitute.org/mpg/depict.
Overlap of gene sets and visualization
A previous version of DEPICT used in analyses of anthropometric traits10,12,13 computed 
gene set overlap by imposing a threshold on which genes belong to a given reconstituted 
gene set and then used the Jaccard index to compute pairwise overlaps. Overlapping 
reconstituted gene sets were grouped as pathway families. Here, we instead computed the 
pairwise Pearson correlation between all reconstituted gene sets and then used the Affinity 
Propagation method37 to group similar reconstituted gene sets. We named each cluster 
(‘meta gene set’) by the name of the representative gene set automatically identified by the 
Affinity Propagation method (for examples, see the top 10 gene set enrichment meta gene 
sets for Crohn’s disease, height and LDL in Supplementary Data 14–16). The R software35 
and a R version of the Affinity Propagation method38 was used setting the parameters 
‘maxits’ to 10,000 and ‘convits’ to 1,000 to ensure conversion when thousands of 
reconstituted gene sets needed to be clustered. We visualized the overlap between pathway 
families pathways using Cytoscape39.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overview of DEPICT
DEPICT is designed to identify likely causal genes, functional or phenotypic gene sets that 
are enriched in genes within associated loci, and tissues or cell types that are implicated by 
the associated loci. DEPICT takes as input a set of trait-associated SNPs and uses them to 
identify independently associated loci that may comprise up to several genes. DEPICT uses 
co-regulation data from 77,840 microarrays to predict genes’ biological functions across 
14,461 gene sets representing a wide spectrum of biological annotations and to construct 
14,461 ‘reconstituted’ gene sets. DEPICT then uses this information to identify reconstituted 
gene sets that enrich for genes in the associated loci, and to prioritize genes at associated 
loci, by identifying genes in different loci that have similar predicted functions. Finally, 
DEPICT relies on 37,427 human gene expression microarrays to assess whether genes in 
associated loci are highly expressed in any of 209 tissue/cell type annotations.
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Figure 2. Comparison of DEPICT and MAGENTA for Crohn’s disease
Comparison of DEPICT, which was run with 63 genome-wide significant Crohn’s disease 
SNPs as input, and MAGENTA, which was run using the complete list of Crohn’s disease 
summary statistics23 (downloaded from www.ibdgenetics.org). DEPICT was run using 
1,280 reconstituted gene sets, and MAGENTA was run using the predefined versions of the 
same 1,280 gene sets. Both methods were run with default settings and non-adjusted 
enrichment P values are plotted.
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Figure 3. DEPICT analysis using GWAS Catalog results
DEPICT identified at least one significant reconstituted gene set for 39 traits and diseases 
from the GWAS Catalog (we investigated 61 traits with at least 10 independent genome-
wide significant loci). (a) Unsupervised clustering of the 39 phenotypes based on their gene 
set enrichment scores across all reconstituted gene sets yielded 7 clusters of phenotypes 
(roughly corresponding to metabolic, lipids, haematological, autoimmune, blood pressure/
cardiac conduction, growth/bone/menopause and a second autoimmune cluster), which 
indicates that DEPICT is able to identify phenotypic-specific and biologically relevant gene 
sets for a wide range of phenotypes. The inset shows that the multiple sclerosis and coeliac 
disease gene set enrichment scores are highly correlated and therefore were clustered within 
the same clade. (b) The number of genome-wide significant loci for a given phenotype was 
positive correlated with the number of significant (FDR<0.05) reconstituted gene sets for 
that phenotype (Pearson r2 = 0.26, t-test P value = 6.86 × 10−5).
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 p
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 d
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 c
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 c
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 m
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 b
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